NCT06476795 The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
| NCT ID | NCT06476795 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Davis |
| Condition | Cardiovascular Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5 participants in total. It began in 2024-06-01 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recently a dietary recommendation of 400 - 600 mg/ day has been proposed for the reduced risk of developing cardiovascular disease. Dietary flavanols can be obtained from the intake of foods such as tea, cocoa, wine, berries and apples. Incorporating Chardonnay Marc (the skins and seeds of Chardonnay grapes) into the diet can be an additional source of dietary flavanols. Like other flavanol-rich foods, Chardonnay Marc provides fiber and polysaccharides that may benefit gut health. This study seeks pilot data on the impact of the daily incorporation of Chardonnay Marc powder into the diet on markers of gut and cardiometabolic health.
Eligibility Criteria
Inclusion Criteria: * Postmenopausal female, with a cessation of menses for at least 2 years * 45-70 years of age * BMI 25- 49.9 kg/m2 * Fasting triglycerides \> 120 mg/dL * Subject is willing and able to comply with the study protocols and procedures. Exclusion Criteria: * Self-reported use of daily anticoagulation agents including aspirin, NSAIDs * Prescription medications and supplements, except for a 6 month stable dose of thyroid medications * Vegan, Vegetarians, food faddists or those consuming a non-traditional diet * Fruit consumption ≥ 3 cups/day * Vegetable consumption ≥ 4 cups/day * Coffee/tea ≥ 3 cups/day * Dark chocolate ≥ 3 oz/day * Self-reported restriction of physical activity due to a chronic health condition * Self-reported chronic/routine high intensity exercise * Blood pressure ≥ 140/90 mm Hg * Self-reported renal or liver disease * Self-reported heart disease, which includes cardiovascular events and stroke, diabetes * Peripheral artery disease Raynaud's syndrome or disease * Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT * Self-reported cancer within past 5 years * Self-reported gastrointestinal disorders, apart from appendix removal * Unwillingness to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements six weeks prior to study enrollment. * Indications of substance or alcohol abuse within the last 3 years * All forms of smoking (e.g. vaping, cigarette, cannabis) * Current enrollee in a clinical research study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06476795 clinical trial?
This trial is open to female participants only, aged 45 Years or older, up to 70 Years, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06476795 currently recruiting?
Yes, NCT06476795 is actively recruiting participants. Contact the research team at rrholt@ucdavis.edu for enrollment information.
Where is the NCT06476795 trial being conducted?
This trial is being conducted at Davis, United States.
Who is sponsoring the NCT06476795 clinical trial?
NCT06476795 is sponsored by University of California, Davis. The trial plans to enroll 5 participants.